Thymus and Activation-regulated Chemokine as a Biomarker for IgG4-related Disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 04 2020
07 04 2020
Historique:
received:
08
11
2019
accepted:
19
03
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
15
12
2020
Statut:
epublish
Résumé
High serum concentrations of thymus and activation-regulated chemokine (TARC) are observed in allergic diseases such as atopic dermatitis and bronchial asthma. Frequent allergic symptoms have been reported in patients with IgG4-related disease (IgG4-RD). We investigated the pathogenic role of TARC as a biomarker in IgG4-RD patients. We evaluated the serum concentrations of TARC from 29 IgG4-RD patients, 28 primary Sjögren syndrome (pSS) patients, and 23 healthy controls (HCs) by enzyme-linked immunosorbent assay (ELISA). We analyzed the correlations between the TARC concentrations and the subjects' clinical parameters. To investigate the biological effect of TARC on the pathogenesis of IgG4-RD, we evaluated the in vitro induction of plasmablasts from IgG4-RD patients by TARC. The serum concentrations of TARC in the IgG4-RD patients were significantly higher than those of the pSS patients and HCs. The serum TARC concentration of the IgG4-RD group was positively correlated with the IgG4-RD responder index (IgG4-RD RI) score and with the number of organs involved, but it was not correlated with the serum IgG4 level or eosinophil number in the IgG4-RD patients' peripheral blood. The patients who had lung involvement had higher serum TARC concentrations. In vitro, TARC clearly induced the formation of plasmablasts from the IgG4-RD patients' peripheral blood mononuclear cells. Collectively, our data suggest that a systemic increment of TARC may contribute to the development of IgG4-RD through an aberrant induction of plasmablasts.
Identifiants
pubmed: 32265499
doi: 10.1038/s41598-020-62941-9
pii: 10.1038/s41598-020-62941-9
pmc: PMC7138842
doi:
Substances chimiques
Biomarkers
0
CCL17 protein, human
0
Chemokine CCL17
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6010Références
Saeki, H. & Tamaki, K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J. dermatological Sci. 43, 75–84, https://doi.org/10.1016/j.jdermsci.2006.06.002 (2006).
doi: 10.1016/j.jdermsci.2006.06.002
Bernardini, G. et al. Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. European journal of immunology 28, 582–588, doi:10.1002/(sici)1521-4141(199802)28:02<582::Aid-immu582>3.0.Co;2-a (1998).
Proudfoot, A. E. Chemokine receptors: multifaceted therapeutic targets. Nat. reviews. Immunology 2, 106–115, https://doi.org/10.1038/nri722 (2002).
doi: 10.1038/nri722
pubmed: 11910892
Mikhak, Z. et al. Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. J. allergy Clin. immunology 123, 67–73 e63, https://doi.org/10.1016/j.jaci.2008.09.049 (2009).
doi: 10.1016/j.jaci.2008.09.049
Kakinuma, T. et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J. allergy Clin. immunology 107, 535–541, https://doi.org/10.1067/mai.2001.113237 (2001).
doi: 10.1067/mai.2001.113237
Kataoka, Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J. Dermatol. 41, 221–229, https://doi.org/10.1111/1346-8138.12440 (2014).
doi: 10.1111/1346-8138.12440
pubmed: 24628072
Sekiya, T. et al. Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 57, 173–177 (2002).
doi: 10.1034/j.1398-9995.2002.5720256.x
Sekiya, T. et al. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J. Immunol. 165, 2205–2213 (2000).
doi: 10.4049/jimmunol.165.4.2205
Perros, F., Hoogsteden, H. C., Coyle, A. J., Lambrecht, B. N. & Hammad, H. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy 64, 995–1002, https://doi.org/10.1111/j.1398-9995.2009.02095.x (2009).
doi: 10.1111/j.1398-9995.2009.02095.x
pubmed: 19630858
Kawasaki, S. et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J. Immunol. 166, 2055–2062 (2001).
doi: 10.4049/jimmunol.166.3.2055
Umehara, H. et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod. Rheumatol. 22, 1–14, https://doi.org/10.1007/s10165-011-0508-6 (2012).
doi: 10.1007/s10165-011-0508-6
pubmed: 21881964
Stone, J. H., Zen, Y. & Deshpande, V. IgG4-related disease. N. Engl. J. Med. 366, 539–551, https://doi.org/10.1056/NEJMra1104650 (2012).
doi: 10.1056/NEJMra1104650
pubmed: 22316447
Inoue, D. et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine 94, e680, https://doi.org/10.1097/MD.0000000000000680 (2015).
doi: 10.1097/MD.0000000000000680
pubmed: 25881845
pmcid: 4602507
Kamisawa, T., Anjiki, H., Egawa, N. & Kubota, N. Allergic manifestations in autoimmune pancreatitis. Eur. J. Gastroenterol. Hepatol. 21, 1136–1139 (2009).
doi: 10.1097/MEG.0b013e3283297417
Aalberse, R. C., Stapel, S. O., Schuurman, J. & Rispens, T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39, 469–477, https://doi.org/10.1111/j.1365-2222.2009.03207.x (2009).
doi: 10.1111/j.1365-2222.2009.03207.x
pubmed: 19222496
Aalberse, R. C., Van Milligen, F., Tan, K. Y. & Stapel, S. O. Allergen-specific IgG4 in atopic disease. Allergy 48, 559–569 (1993).
doi: 10.1111/j.1398-9995.1993.tb00749.x
Kanari, H. et al. Role of Th2 cells in IgG4-related lacrimal gland enlargement. Int. Arch. Allergy Immunol. 152(Suppl 1), 47–53, https://doi.org/10.1159/000312125 (2010).
doi: 10.1159/000312125
pubmed: 20523063
Tanaka, A. et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis rheumatism 64, 254–263, https://doi.org/10.1002/art.33320 (2012).
doi: 10.1002/art.33320
pubmed: 21898360
Mattoo, H., Della-Torre, E., Mahajan, V. S., Stone, J. H. & Pillai, S. Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy 69, 399–402, https://doi.org/10.1111/all.12342 (2014).
doi: 10.1111/all.12342
pubmed: 24382311
Szodoray, P., Alex, P., Brun, J. G., Centola, M. & Jonsson, R. Circulating cytokines in primary Sjogren’s syndrome determined by a multiplex cytokine array system. Scand. J. Immunol. 59, 592–599, https://doi.org/10.1111/j.0300-9475.2004.01432.x (2004).
doi: 10.1111/j.0300-9475.2004.01432.x
pubmed: 15182255
Tsuboi, H. et al. Primary and secondary surveys on epidemiology of Sjogren’s syndrome in Japan. Mod. Rheumatol. 24, 464–470, https://doi.org/10.3109/14397595.2013.843765 (2014).
doi: 10.3109/14397595.2013.843765
pubmed: 24252039
Zen, Y. & Nakanuma, Y. IgG4-related disease: a cross-sectional study of 114 cases. Am. J. Surg. Pathol. 34, 1812–1819, https://doi.org/10.1097/PAS.0b013e3181f7266b (2010).
doi: 10.1097/PAS.0b013e3181f7266b
pubmed: 21107087
Umehara, H. et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod. Rheumatol. 22, 21–30, https://doi.org/10.1007/s10165-011-0571-z (2012).
doi: 10.1007/s10165-011-0571-z
pubmed: 22218969
Toyoshima, M. et al. IgG4-related lung disease in a worker occupationally exposed to asbestos. Intern. Med. 49, 1175–1178 (2010).
doi: 10.2169/internalmedicine.49.3314
Fazilleau, N., Mark, L., McHeyzer-Williams, L. J. & McHeyzer-Williams, M. G. Follicular helper T cells: lineage and location. Immunity 30, 324–335, https://doi.org/10.1016/j.immuni.2009.03.003 (2009).
doi: 10.1016/j.immuni.2009.03.003
pubmed: 19303387
pmcid: 2731675
Maehara, T. et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Ann. rheumatic Dis. 71, 2011–2019, https://doi.org/10.1136/annrheumdis-2012-201477 (2012).
doi: 10.1136/annrheumdis-2012-201477
Wallace, Z. S. et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann. rheumatic Dis. 74, 190–195, https://doi.org/10.1136/annrheumdis-2014-205233 (2015).
doi: 10.1136/annrheumdis-2014-205233
Lanzillotta, M. et al. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. Clin. Exp. Rheumatol. 37(Suppl 118), 159–166 (2019).
pubmed: 30652677
Mattoo, H. et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J. allergy Clin. immunology 134, 679–687, https://doi.org/10.1016/j.jaci.2014.03.034 (2014).
doi: 10.1016/j.jaci.2014.03.034
Akiyama, M. et al. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Res. Ther. 18, 167, https://doi.org/10.1186/s13075-016-1064-4 (2016).
doi: 10.1186/s13075-016-1064-4
pubmed: 27411315
pmcid: 4944254
Johansson, C. et al. Differential expression of chemokine receptors on human IgA+ and IgG+ B cells. Clin. Exp. Immunol. 141, 279–287, https://doi.org/10.1111/j.1365-2249.2005.02843.x (2005).
doi: 10.1111/j.1365-2249.2005.02843.x
pubmed: 15996192
pmcid: 1809445
Wallace, Z. S. et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care Res. 70, 1671–1678, https://doi.org/10.1002/acr.23543 (2018).
doi: 10.1002/acr.23543
Shiboski, C. H. et al. American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann. rheumatic Dis. 76, 9–16, https://doi.org/10.1136/annrheumdis-2016-210571 (2017).
doi: 10.1136/annrheumdis-2016-210571